(Q24201908)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23775773%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

meta-analysis

0 references

title

Interferon alpha for the adjuvant treatment of cutaneous melanoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23775773%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23775773%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Pierluigi Pilati

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23775773%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Vanna Chiarion Sileni

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23775773%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

author name string

Simone Mocellin

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23775773%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Marko B Lens

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23775773%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

publication date

18 June 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23775773%20AND%20SRC:MED&resulttype=core&format=json

Cochrane Database of Systematic Reviews

3 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23775773%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23775773%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

page(s)

CD008955

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23775773%20AND%20SRC:MED&resulttype=core&format=json

Adjuvant interferon alpha 2b in high risk melanoma - the Scottish study

3 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008955.PUB2

Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008955.PUB2

Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008955.PUB2

Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008955.PUB2

Adjuvant low-dose interferon {alpha}2a with or without dacarbazine compared with surgery alone: a prospective-randomized phase III DeCOG trial in melanoma patients with regional lymph node metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008955.PUB2

Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008955.PUB2

Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008955.PUB2

Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008955.PUB2

Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008955.PUB2

High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008955.PUB2

Adjuvant high-dose interferon for cutaneous melanoma is most beneficial for patients with early stage III disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008955.PUB2

Interferon-gamma or granulocyte-macrophage colony-stimulating factor administered as adjuvants with a vaccine of irradiated autologous tumor cells from short-term cell line cultures: a randomized phase 2 trial of the cancer biotherapy research group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008955.PUB2

Prospective randomized multicenter adjuvant dermatologic cooperative oncology group trial of low-dose interferon alfa-2b with or without a modified high-dose interferon alfa-2b induction phase in patients with lymph node-negative melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008955.PUB2

Efficacy of low-dose interferon {alpha}2a 18 versus 60 months of treatment in patients with primary melanoma of >= 1.5 mm tumor thickness: results of a randomized phase III DeCOG trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008955.PUB2

A randomized phase III trial of biochemotherapy versus interferon-alpha-2b for adjuvant therapy in patients at high risk for melanoma recurrence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008955.PUB2

Randomized trial of adjuvant human interferon gamma versus observation in high-risk cutaneous melanoma: a Southwest Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008955.PUB2

Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon Alfa-2b compared with high-dose interferon Alfa-2b for Resected stage III cutaneous melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008955.PUB2

Prospective, randomized, multicenter, double-blind placebo-controlled trial comparing adjuvant interferon alfa and isotretinoin with interferon alfa alone in stage IIA and IIB melanoma: European Cooperative Adjuvant Melanoma Treatment Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008955.PUB2

Calculating the number needed to treat for trials where the outcome is time to an event

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008955.PUB2

Adjuvant therapy of melanoma with interferon: lessons of the past decade

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008955.PUB2

Adjuvant use of interferon alpha 2b is not justified in patients with stage IIb/III melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008955.PUB2

Final version of 2009 AJCC melanoma staging and classification

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008955.PUB2

Interferons at age 50: past, current and future impact on biomedicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008955.PUB2

Adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma: a phase III randomized controlled trial of health-related quality of life and symptoms by the European Organisation for Research and Treatment of C

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008955.PUB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008955.PUB2

Interferon alpha and CPG oligodeoxynucleotides elicit additive immunostimulatory and antitumor effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008955.PUB2

Neurotoxicity of interferon-alpha in melanoma therapy: results from a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008955.PUB2

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008955.PUB2

Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: an Eastern Cooperative Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008955.PUB2

Assessment of patient-reported outcomes in patients with melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008955.PUB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008955.PUB2

Systemic treatments for metastatic cutaneous melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008955.PUB2

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008955.PUB2

Quality of life and cost-effectiveness of interferon-alpha in malignant melanoma: results from randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008955.PUB2

Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008955.PUB2

Management of melanoma: a European perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008955.PUB2

Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008955.PUB2

Where are we with adjuvant therapy of stage III and IV melanoma in 2009?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008955.PUB2

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008955.PUB2

Interferon-alpha and transforming growth factor-beta co-induce growth inhibition of human tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008955.PUB2

Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008955.PUB2

Chemotherapy for metastatic melanoma: time for a change?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008955.PUB2

Practical guidelines for the management of interferon-alpha-2b side effects in patients receiving adjuvant treatment for melanoma: expert opinion

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008955.PUB2

Quantifying heterogeneity in a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008955.PUB2

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008955.PUB2

Patient preferences for adjuvant interferon alfa-2b treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008955.PUB2

A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008955.PUB2

Does pegylated interferon alpha-2b confer additional benefit in the adjuvant treatment of high-risk melanoma?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008955.PUB2

Raf inhibitor stabilizes receptor for the type I interferon but inhibits its anti-proliferative effects in human malignant melanoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008955.PUB2

Interferon alfa therapy for malignant melanoma: a systematic review of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008955.PUB2

Global perspectives of contemporary epidemiological trends of cutaneous malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008955.PUB2

Cutaneous melanoma: interferon alpha adjuvant therapy for patients at high risk for recurrent disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008955.PUB2

IFN-alpha and bortezomib overcome Bcl-2 and Mcl-1 overexpression in melanoma cells by stimulating the extrinsic pathway of apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008955.PUB2

Modulation of SOCS protein expression influences the interferon responsiveness of human melanoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008955.PUB2

Treatments for metastatic melanoma: synthesis of evidence from randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008955.PUB2

The prognostic value of circulating tumor cells in patients with melanoma: a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008955.PUB2

Sentinel lymph node molecular ultrastaging in patients with melanoma: a systematic review and meta-analysis of prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008955.PUB2

Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008955.PUB2

Targeted Therapy Database (TTD): a model to match patient's molecular profile with current knowledge on cancer biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008955.PUB2

Cutaneous melanoma in situ: translational evidence from a large population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008955.PUB2

The impact of surgery on survival of patients with cutaneous melanoma: revisiting the role of primary tumor excision margins

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008955.PUB2

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008955.PUB2

Sentinel-node biopsy or nodal observation in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008955.PUB2

Present role and future potential of type I interferons in adjuvant therapy of high-risk operable melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008955.PUB2

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008955.PUB2

The anticancer face of interferon alpha (IFN-alpha): from biology to clinical results, with a focus on melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008955.PUB2

Early (sentinel lymph node biopsy-guided) versus delayed lymphadenectomy in melanoma patients with lymph node metastases : personal experience and literature meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008955.PUB2

Interferon alpha as adjuvant postsurgical treatment of melanoma: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008955.PUB2

Presence of tumor-infiltrating lymphocytes and a dominant nodule within primary melanoma are prognostic factors for relapse-free survival of patients with thick (t4) primary melanoma: pathologic analysis of the e1690 and e1694 intergroup trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008955.PUB2

Chemoimmunotherapy versus chemotherapy for metastatic malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008955.PUB2

Surgical excision margins for primary cutaneous melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008955.PUB2

Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008955.PUB2

Management of metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008955.PUB2

Type I interferons (alpha/beta) in immunity and autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008955.PUB2

Melanoma--part 2: management

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008955.PUB2

Cutaneous melanoma in the era of molecular profiling

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008955.PUB2

Practical methods for incorporating summary time-to-event data into meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008955.PUB2

Management of cutaneous melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008955.PUB2

Systematic review of systemic adjuvant therapy for patients at high risk for recurrent melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008955.PUB2

Management of cutaneous melanoma: a public health and individual patient care perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008955.PUB2

Effects of high-dose IFNalpha2b on regional lymph node metastases of human melanoma: modulation of STAT5, FOXP3, and IL-17.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008955.PUB2

Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008955.PUB2

The FACT-Melanoma quality-of-life instrument: comparison of a five-point and four-point response scale using the Rasch measurement model

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008955.PUB2

Multiplex analysis of serum cytokines in melanoma patients treated with interferon-alpha2b.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008955.PUB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008955.PUB2

Postsurgical adjuvant therapy for melanoma. Evaluation of a 3-year randomized trial with recombinant interferon-alpha after 3 and 5 years of follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008955.PUB2

7 January 2021

Final results of the EORTC 18871/DKG 80-1 randomised phase III trial. rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metast

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008955.PUB2

7 January 2021

A randomised phase II trial of 1 month versus 1 year of adjuvant high-dose interferon α-2b in high-risk acral melanoma patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008955.PUB2

7 January 2021

Results of a prospective randomized trial using DTIC and interferon as adjuvant therapy for stage I malignant melanoma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008955.PUB2

7 January 2021

Adjuvant therapy with high-dose interferon alpha 2b in patients with high-risk stage IIB/III melanoma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008955.PUB2

7 January 2021

Cutaneous malignant melanoma: ESMO clinical recommendations for diagnosis, treatment and follow-up

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008955.PUB2

7 January 2021

Utility of adjuvant systemic therapy in melanoma.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008955.PUB2

7 January 2021

Recombinant interferon alpha-2b and coenzyme Q10 as a postsurgical adjuvant therapy for melanoma: a 3-year trial with recombinant interferon-alpha and 5-year follow-up

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008955.PUB2

7 January 2021

Long-term adjuvant therapy of high-risk malignant melanoma with interferon alpha 2b

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008955.PUB2

7 January 2021

Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008955.PUB2

7 January 2021

Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008955.PUB2

7 January 2021

High-dose interferon alfa-2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: results of the Multicenter Eastern Cooperative Oncology Group Phase II Trial E2696

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008955.PUB2

7 January 2021

High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008955.PUB2

7 January 2021

Prospective randomized trial of interferon alfa-2b and interleukin-2 as adjuvant treatment for resected intermediate- and high-risk primary melanoma without clinically detectable node metastasis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008955.PUB2

7 January 2021

Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008955.PUB2

7 January 2021

Randomized phase III study of 1 month versus 1 year of adjuvant high-dose interferon alfa-2b in patients with resected high-risk melanoma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008955.PUB2

7 January 2021

Adjuvant interferon in high-risk melanoma: end of the era?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008955.PUB2

7 January 2021

10.1002/14651858.CD008955.PUB2

Identifiers

DOI

2 references

Consolidated OpenCitations Corpus – April 2017

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23775773%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

1 reference

Consolidated OpenCitations Corpus – April 2017

2 references

Consolidated OpenCitations Corpus – April 2017